Vir/GSK Move Lead Coronavirus Antibody Into Phase III

Safety In 20 Phase II Patients Enabled Testing In 1,300 People

 
• By Mandy Jackson

Results from a Phase II/III study for VIR-7831 in the prevention of hospitalization due to COVID-19 are expected in late 2020 and early 2021.

Immunological system, antibodies attacking the virus covid-19. 3D illustration, concept of the body's defense system. Y-shaped antibody attacking the coronavirus.
VIR-7831 is engineered to neutralize SARS-CoV-2, with limited treatment resistance, enhanced lung bioavailability and an extended half-life • Source: Shutterstock

More from COVID-19

More from Scrip